卡立普嗪辅助治疗氯氮平反应欠佳：两例报告
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.
作者信息
Berardis Domenico De, Rapini Gabriella, Olivieri Luigi, Giardini Agostina, Lauretis Ida De, Serroni Nicola, Orsolini Laura, Fornaro Michele, Iasevoli Felice, Trotta Sabatino, Cottura Paolo, Vellante Federica, Alessandrini Marco, Giannantonio Massimo Di
机构信息
National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini," Teramo, Italy.
Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. d'Annunzio," Chieti, Italy.
出版信息
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178. doi: 10.9758/cpn.2021.19.1.174.
Abstract
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D/D receptors with preferential binding to the D receptor, antagonism of 5HT receptors, and partial agonism of 5HT. Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
摘要
卡立哌嗪是一种新型抗精神病药物，它对多巴胺D2/D3受体具有部分激动作用，对D3受体具有优先结合力，对5-HT2A受体具有拮抗作用，对5-HT1A受体具有部分激动作用。目前，卡立哌嗪已在精神分裂症患者、双相情感障碍患者中显示出临床疗效，以及在重度抑郁症（MDD）患者和难治性MDD患者中的辅助治疗效果。在本病例系列中，我们报告了两名难治性精神分裂症患者，他们对氯氮平有部分反应，联合使用卡立哌嗪后获益。卡立哌嗪联合使用在改善氯氮平的不良代谢效应方面也有显著效果。
相似文献
1
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178. doi: 10.9758/cpn.2021.19.1.174.
2
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review.
Ther Adv Psychopharmacol. 2022 Jan 28;12:20451253211066642. doi: 10.1177/20451253211066642. eCollection 2022.
3
The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.
Curr Pharm Des. 2016;22(33):5144-5162. doi: 10.2174/1381612822666160701084447.
4
Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone - Clinical Cases.
Neuropsychiatr Dis Treat. 2022 Jun 9;18:1145-1149. doi: 10.2147/NDT.S343747. eCollection 2022.
5
Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Clin Schizophr Relat Psychoses. 2016 Summer;10(2):109-19. doi: 10.3371/1935-1232-10.2.109.
6
Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
Curr Opin Investig Drugs. 2010 Jul;11(7):823-32.
7
Cariprazine in Three Special Different Areas: A Real-World Experience.
Neuropsychiatr Dis Treat. 2021 Dec 7;17:3581-3588. doi: 10.2147/NDT.S335332. eCollection 2021.
8
The Role of Dopamine D Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens.
J Pharmacol Exp Ther. 2019 Nov;371(2):517-525. doi: 10.1124/jpet.119.259879. Epub 2019 Sep 11.
9
Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
Expert Rev Neurother. 2013 Nov;13(11):1141-59. doi: 10.1586/14737175.2013.853448.
10
Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome.
Clin Psychopharmacol Neurosci. 2022 May 31;20(2):398-401. doi: 10.9758/cpn.2022.20.2.398.
引用本文的文献
1
Cariprazine and clozapine: a systematic review of a promising antipsychotic combination for treatment-resistant schizophrenia.
Int J Neuropsychopharmacol. 2025 Aug 1;28(8). doi: 10.1093/ijnp/pyaf053.
2
Cariprazine in the management of emotionally unstable personality disorder in female patients: a case series.
Front Psychiatry. 2024 Jul 8;15:1421698. doi: 10.3389/fpsyt.2024.1421698. eCollection 2024.
3
The management of patients with predominant negative symptoms in Slovakia: A 1-year longitudinal, prospective, multicentric cohort study.
Eur Psychiatry. 2024 May 23;67(1):e44. doi: 10.1192/j.eurpsy.2024.1757.
4
Cariprazine augmentation in a patient with clozapine-resistant schizophrenia.
Ind Psychiatry J. 2023 Nov;32(Suppl 1):S279-S280. doi: 10.4103/ipj.ipj_208_23. Epub 2023 Nov 30.
5
Cariprazine augmentation of clozapine in schizophrenia-a retrospective chart review.
Front Pharmacol. 2024 Jan 4;14:1321112. doi: 10.3389/fphar.2023.1321112. eCollection 2023.
6
Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts' Opinion using a Delphi Approach.
Curr Neuropharmacol. 2023;21(11):2206-2216. doi: 10.2174/1570159X21666230719162023.
7
Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review.
Brain Sci. 2023 Mar 4;13(3):445. doi: 10.3390/brainsci13030445.
8
Cariprazine - an Alternative Treatment for Clozapine-resistant Schizophrenia?
Clin Psychopharmacol Neurosci. 2023 Feb 28;21(1):202-206. doi: 10.9758/cpn.2023.21.1.202.
9
Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
Front Psychiatry. 2022 Nov 29;13:1069432. doi: 10.3389/fpsyt.2022.1069432. eCollection 2022.
10
Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study.
Ther Adv Psychopharmacol. 2022 Nov 21;12:20451253221132087. doi: 10.1177/20451253221132087. eCollection 2022.
本文引用的文献
1
Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection: a case report.
Int Clin Psychopharmacol. 2020 Mar;35(2):113-118. doi: 10.1097/YIC.0000000000000284.
2
[Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].
Neuropsychopharmacol Hung. 2019 Sep;21(3):103-118.
3
The Role of Dopamine D Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens.
J Pharmacol Exp Ther. 2019 Nov;371(2):517-525. doi: 10.1124/jpet.119.259879. Epub 2019 Sep 11.
4
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. doi: 10.1016/j.euroneuro.2019.06.008. Epub 2019 Jun 27.
5
Neural Networks in Neurological and Psychiatric Diseases.
Curr Pharm Des. 2019;25(4):374-375. doi: 10.2174/138161282504190516080951.
6
Metabolic Syndrome Reversal With Cariprazine.
J Clin Psychopharmacol. 2019 Jul/Aug;39(4):413-416. doi: 10.1097/JCP.0000000000001074.
7
A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients.
Expert Rev Clin Pharmacol. 2019 Jul;12(7):603-621. doi: 10.1080/17512433.2019.1617695. Epub 2019 May 31.
8
The role of dopamine D receptors in the mechanism of action of cariprazine.
CNS Spectr. 2020 Jun;25(3):343-351. doi: 10.1017/S109285291900083X. Epub 2019 Apr 23.
9
Cariprazine for the treatment of bipolar depression: a review.
Expert Rev Neurother. 2019 Apr;19(4):317-323. doi: 10.1080/14737175.2019.1580571. Epub 2019 Feb 20.
10
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.
Eur Psychiatry. 2019 May;58:1-9. doi: 10.1016/j.eurpsy.2019.01.015. Epub 2019 Feb 7.
Zotero 插件